ASCO 2022
Paradigm shift in breast cancer: Where do we use the treatment option? How do we test HER2 status? How can we manage toxicity?
Destiny-Breast04
ASCO 2022
Paradigm shift in breast cancer: Where do we use the…
ASCO 2022
Transatlantic differences in ADC side effects…
PALOMA-2
ASCO 2022
What are the cosenquences of the new OS data for CDK4/6…
TROPiCS-02
ASCO 2022
More data needed: Are the results clinical meaningful?…
MAINTAIN
ASCO 2022
CDK4/6i switch: who benefits from switching the CDK4/6…
TROPiCS-02
ASCO 2022
What clincial value has statistical signifcance? How…
Tropics02; Destiny-Breast04
ASCO 2022
Patients perspectives: ADCs - how do manage the new,…
MAINTAIN
ASCO 2022
How to determine progress of disease? How to proceed…
Destiny-Breast04; U31402-A-J101; PALOMA-2; MAINTAIN
ASCO 2022
ADCs & CDK4/6i - paradigm shifts and therapy switches…
Destiny-Breast04
ASCO 2022
Determining HER2 receptor expression: How do we target…
DESTINY-Breast04; TROPiCS-02
ASCO 2022
Breakthrough news with antibody drug conjugate
Destiny-Breast04
ASCO 2022
T-DxD should be the new SoC for Her2low MBC patients
PALOMA-2
ASCO 2022
Disappoiting final OS data and its implications for our…
PALOMA-2; MAINTAIN
ASCO 2022
No changes in clinical practice after new CDK4/6i-data
PALOMA-2
ASCO 2022
Possible explanations of the negative study
Tropics02; Destiny-Breast04
ASCO 2022
Fascinating data of ADCs in breast cancer at ASCO22
NRG-BR002
ASCO 2022
Discontiunation of trial is disappointing despite…
PALOMA-2
ASCO 2022
Palbociclib - Overall survival data
ASCO 2022
Patritumab Deruxtecan: HER3-targeted ADC in HER3…
NRG-BR002
ASCO 2022
No effect for local treatment of metastasis
Destiny-Breast04, Destiny-Breast03, TROPiCS-2, PALOMA-2, MAINTAIN, NRG-BR002
ASCO 2022
My ASCO22 highlights in metastatic breast cancer
TROPICS-02; Destiny-Breast04
ASCO 2022
Exciting advances across a wide subset of breast…
Destiny-Breast04
ASCO 2022
Gamechanger in breast cancer
MAINTAIN
ASCO 2022
Benefit of CDK4/6 Switch after Progression
TROPiCS-02
ASCO 2022
SG may be a good option for pre-treated HR+/Her2- pts
Destiny-Breast04
ASCO 2022
Exciting and practice changing news for HR+/Her2low MBC…
FAKTION
ASCO 2022
Option for overcoming endocrine resistance?
NRG-BR002
ASCO 2022
Oligometastasis: no advantage of additional…
BioItaLEE
ASCO 2022
Combination of ctDNA and TKa assesment may improve…
coopERA BC
ASCO 2022
Combi SERD + Palbo reduces proliferation better than…
Destiny-Breast04
ASCO 2022
Revolution in the field of HR+ disease
MAINTAIN
ASCO 2022
First evidence on benefit of CDK4/6 inhibitors beyond…
NeoSTAR
ASCO 2022
Sacituzumab govitecan improves PCr in patients with…
Destiny-Breast04
ASCO 2022
New standard of care for HR+/Her2low patients
TROPiCS-02
ASCO 2022
Smart chemotherapy improves PFS
FAKTION
ASCO 2022
Improvment of PFS & OS with activated alteration…
Destiny-Breast 04; Tropics-02
ASCO 2022
Impressive and practice changing data of ADCs mark the…
ASTER
ASCO 2022
Endocrine therapy alone is important in treatment of…
Destiny-Breast04
ASCO 2022
Practice changing data
Tropics02
ASCO 2022
SG is a new therapy option for HR+/HER2- MBC patients
Destiny-Breast04
ASCO 2022
New SoC for large subpopulation of breast cancer…
TROPiCS-02
ASCO 2022
ADC: future therapeutic option in advanced HR+/HER2 BC
Tropics02
ASCO 2022
Good therapeutic option in HR+ HER2- mBC after failure…
DESTINY-Breast04; TROPiCS-02
ASCO 2022
New agents for the clincial practice
MAINTAIN
ASCO 2022
Additional administration of ribociclib improves PFS…
PALOMA-2; MAINTAIN
ASCO 2022
PALOMA2 e MAINTAIN: cosa cambia nella pratica clinica?
DESTINY-Breast04; TROPiCS-02
ASCO 2022
ADCs en cáncer de mama con receptores hormonales…
Destiny-Breast04, Tropics-02
ASCO22
Noutăți inovatoare cu conjugatul de medicamente cu…
MAINTAIN
ASCO 2022
Pierwsze dane nt. skuteczności inhibitorów CDK4/6 po…
TROPiCS-02
ASCO 2022
Il sacituzumab govitecan migliora il PFS nei tumori…
BioItaLEE
ASCO 2022
La valutazione combinata di ctDNA e TKa può aiutare a…
Destiny-Breast 04; Tropics-02
ASCO 2022
Les nouvelles données impressionnantes des ADC à l’ASCO…
Destiny-Breast04
ASCO 2022
Novità entusiasmanti e practice changing per le…
Destiny-Breast04
ASCO 2022
Una rivoluzione per il tumore mammario…
Tropics02
ASCO 2022
SG come nuova opzione di cura per le pazienti con…
Destiny-Breast 04; Tropics-02
ASCO 2022
I nuovi impressionanti risultati degli ADC a l’ASCO…
Destiny-Breast04
ASCO 2022
Nowy standard dla znaczącej subopulacji chorych na raka…
Aster 70s
ASCO 2022
CT benefit for elderly patients, if they are able to…
ABCSG-18
ASCO 2022
Long term overall survival benefit of Denosumab in…
ASTRRA
ASCO 2022
Ovarian function suppression - it is here to stay!
LUMINA
ASCO 2022
Adding towards deescalation in luminal A EBC by…
KEYNOTE-522; NeoSTAR
ASCO 2022
Neoadjuvant Pembro decreased RCB. SG - first promising…
ADAPT
ASCO 2022
High concordance of local, central IHC and RT-PCR for…
iSPY-2, Keynote-522, ASTER-70s, ASTRRA, ABCSG-18
ASCO 2022
My ASCO22 highlights in early breast cancer
coopERA BC
ASCO 2022
Combi SERD + Palbo redzuert proliferation better than…
CheckMate 227; CheckMate 9LA; FDA pooled
ASCO 2022
Immunotherapy - Part 1
CHRYSALIS-2; CHRYSALIS
ASCO 2022
Molecular landscape - Part 2
KRYSTAL-1
ASCO 2022
Molecular landscape - Part 1
Lung-MAP
ASCO 2022
Immunotherapy - Part 2
ASCO 2022
CLN-081 is a promising new agent for EGFR exon 20…
CHRYSALIS
ASCO 2022
New treatment options for METexon 14 skipping:…
CHRYSALIS-2; CHRYSALIS
ASCO 2022
New components and therapies for advanced NSCLC
COSMIC-021
ASCO 2022
COSMIC-021: Not practice-changing, but interesting…
CHRYSALIS
ASCO 2022
New option in patients harboring METex14 mutation
FDA pooled analysis
ASCO 2022
Strategies for PD-L1 > 50%
CHRYSALIS
ASCO 2022
Bispecific Antibodies - the cMET field is moving
CHRYSALIS-2
ASCO 2022
A chemo-free option in patients with EGFR-mutation
KRYSTAL-1
ASCO 2022
KRASG12C mutation: Adagrasib is comparabale to…
CHRYSALIS
ASCO 2022
Amivantamab as a future option for METex14 patients?
KRYSTAL-1
ASCO 2022
Is adagrasib an alternative to sotorasib?
KRYSTAL-1
ASCO 2022
In the second line: Options for Immunotherapy…
CodeBreaK100
ASCO 2022
Multiple aquired resistance mutations may drive disease…
FDA pooled
ASCO 2022
Role of IO and chemo-IO in patients with PD-L1 > 50%
ASCO 2022
CLN-081 for patients with metastatic NSCLC and an…
KRYSTAL-1
ASCO 2022
Promising results for pre-treated patients with…
Lung-MAP; KRYSTAL-1
ASCO 2022
Options after progression to chemo/IO and for KRASG12C…
FDA pooled analysis
ASCO 2022
PD-L1 over 50%: Chemo-IO or IO?
KRYSTAL-1
ASCO 2022
L’adagrasib, inhibiteur de la mutation KRASG12C: une…
ASCO 2022
Was tun nach Versagen einer Chemoimmun-Therapie?
COSMIC-021
ASCO 2022
COSMIC-021: Nicht praxisverändernd, aber interessante…
CHRYSALIS
ASCO 2022
Une nouvelle option, l’amivantamab, en situation de…
KRYSTAL-1
ASCO 2022
Veelbelovende resultaten voor voorbehandelde patienten…
KRYSTAL-1; Lung-MAP
ASCO 2022
Segunda Linea: opciones tras resistencia a…
ASCO 2022
CLN-081 voor patienten met gemetastaseerd NSCLC en een…
ASCO 2022
Bispezifische Antikörper - Neues von CHRYSALIS
CHRYSALIS-2; CHRYSALIS
ASCO 2022
Nuevas terapias para el CPCNP avanzado
CHRYSALIS
ASCO 2022
Nieuwe behandelopties voor METexon 14 skipping:…
ASCO 2022
PD-L1 über 50 % - was tun?
FDA pooled
ASCO 2022
Die Rolle von IO und Chemo-IO bei Patienten mit PD-L1 >…
NADIM II; CheckMate 816
ASCO 2022
Neoadjuvant and adjuvant therapy - Part 1
NADIM II; CheckMate 816
ASCO 2022
Neoadjuvant and adjuvant therapy - Part 2
CheckMate-816
ASCO 2022
CheckMate-816: Neoadjuvant therapy
NADIM II
ASCO 2022
A new option in neoadjuvant chemoimmunotherapy
NADIM-II
ASCO 2022
NADIM-II strengthens the findings from CheckMate-816
KEYNOTE-799
ASCO 2022
New treatment approaches in Stage III
NADIM II
ASCO 2022
Perspectives on multimodality
NADIM II
ASCO 2022
Chimiothérapie néoadjuvante des stades III , vers un…
KEYNOTE-799
ASCO 2022
Neue Ansätze im Stadium III
SKYSCRAPER-02
ASCO 2022
No benefit for tiragolumab / novel anti-PD-1 mAB…
SKYSCRAPER-02
ASCO 2022
SKYSCRAPER-02: Subgroups could be important
ASCO 2022
Immuncheckpoint-inhibitor therapy
SKYSCRAPER-02
ASCO 2022
SCLC-Update: No benefit with Tiragolumab/Chemo-IO is…
SKYSCRAPER-02
ASCO 2022
Le Tiragolumab n’apporte pas de bénéfice à la…
TheraP; VISION
ASCO 2022
mCRPC: LuPSMA - new treatment option in mCRPC
ENZAMET; ARASENS
ASCO 2022
mHSPC: Transatlantic differences in genetic testing &…
Propel; MAGNITUDE; BRCAAWAY
ASCO 2022
PARP inhibitors in mCRPC: Do we need more genetic…
VISION
ASCO 2022
SUV mean at PET images as a prognostic tool for PSMA…
ENZAMET
ASCO 2022
ADT alone is no longer standard of care
The highlights in GU cancers of ASCO22
ASCO 2022
The highlights in GU cancers of ASCO22
ASCO 2022
Ongoing trial invetiagting the impact of…
VISION
ASCO 2022
Further updates from the VISION trial
ENZAMET
ASCO 2022
No big scoop, but encouraging results
ENZAMET
ASCO 2022
The efficacy of doublets in mHSPC
ASCO 2022
Phase 1 study on combining LuPSMA treatment with…
ASCO 2022
Surrogate endpoints in mHSPC
TheraP
ASCO 2022
3 year overall survival of TheraP study
ARAMIS
ASCO 2022
Frequent imaging for early detection of metastases in…
BRCAAWAY
ASCO 2022
Arbiraterone + Olaparib: Is it synergistic?
TheraP
ASCO 2022
LuPSMA & cabazitaxel are better than SoC alone
ARASEC
ASCO 2022
Value of triple-therapy - complimentary study to…
CHART
ASCO 2022
SHR3680 - do we need a new androgen receptor inhibitor
TheraP
ASCO 2022
TheraP shows no difference in overall survival between…
VISION
ASCO 2022
Lu-PSMA effective regardless of prior or concomitant…
ASCO 2022
GGT impacts PCa patients care
TheraP
ASCO 2022
Lu-PSMA in the third line
Vision
ASCO 2022
SUVmean is highly predictive of better PFS and OS
ASCO 2022
PFS good surrogate endpoint for overall survival
ASCO 2022
Pas de nouvelles sensationnelles mais des données…
ASCO 2022
Kombination av 177-LU-PSMA-617 och pembrolizumab I Fas…
ASCO 2022
Tidigare endpoints I mHSPC studier
ASCO 2022
Lo mas destacado en tumores GU en ASCO 2022
VISION
ASCO 2022
Kvantifiering av PMSA PET upptaget som prognostisk…
TheraP
ASCO 2022
Treårs överlevnadsresultat i TheraP studien.
EVEREST
ASCO 2022
EVEREST: Inisghts from the negative trial
CLEAR Study; KEYNOTE-426; CheckMate (CM) 214; CheckMate 9ER
ASCO 2022
Combination Therapy is State of the Art in Metastatic…
CheckMate214
ASCO 2022
The relevance of quality of life in kidney cancer!
CheckMate9ER
ASCO 2022
What are the consequences for future trial design?
EVEREST
ASCO 2022
Should Everolimus be revisited for high-risk patients?
ASCO 2022
Importance of health related quality of life
EVEREST
ASCO 2022
Should we be looking at Everolimus in the future?
CheckMate 9ER; CheckMate 214
ASCO 2022
QoL & DepOR correlate with clinical outcomes - reminder…
CheckMate 9ER
ASCO 2022
Depth of remission in firstline
ASCO 2022
PSMA-PET may improve imaging of clear cell RCC
LITESPARK-004
ASCO 2022
Belzutifann shows good tumor activity in renal cancer
LITESPARK-004
ASCO 2022
Clear evidence for durable benefit for patients with…
KEYNOTE-426
ASCO 2022
Combi Axi + Pembro also successful with good risk…
The highlights in GU cancers of ASCO22
ASCO 2022
The highlights in GU cancers of ASCO22
ASCO 2022
Pas de nouvelles sensationnelles mais des données…
ASCO 2022
Lo mas destacado en tumores GU en ASCO 2022
AURA; SAKK 06/17; JAVELIN
ASCO 2022
The role of systemic treatment in the pre-operative…
COSMIC-021
ASCO 2022
New data on TKi utilization in bladder cancer
EV-103; RC-48
ASCO 2022
ADCs: do we enter a new era of therapy for urothelial…
The highlights in GU cancers of ASCO22
ASCO 2022
The highlights in GU cancers of ASCO22
SAKK 06/17
ASCO 2022
Perioperative immuno-chemotherapy in MIBC
COSMIC-021; ATLANTIS
ASCO 2022
The end of of VEGF-targeted therapy in urothelial…
EV-301; RC48-ADC
ASCO 2022
Exciting future for ADCs
ENZAMET
ASCO 2022
No big scoop, but encouraging results
ASCO 2022
Maintenance concepts
ASCO 2022
BCG failure
ATLANTIS; MAIN_CAV
ASCO 2022
My highlights of metastasized urothelial cancer
ASCO 2022
ADCs: News from ASCO 2022
CREST cohort B
ASCO 2022
Investigating sasanlimab in BCG-unresponsive NMIBC
QUILT 3.032; SWOG S1314
ASCO 2022
My highlights in localized urothelial cancer
ASCO 2022
Lo mas destacado en tumores GU en ASCO 2022
ASCO 2022
Σημαντικά μηνύματα για τον ουροθηλιακό καρκίνο από το…
ASCO 2022
Systemic therapy
ASCO 2022
Radiotherapy as a new standard for cisplatin ineligible…
ASCO 2022
Precision oncology - NTRK worth to search the patients
ASCO 2022
News from Sarcoma
ASCO 2022
Few testicular tumors after 5 years
ASCO22
Opportunities & challenges of cancer genetics
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!